Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019.

Kristina Elizabeth Neergaard ClarkWilliam D NevinTabitha MahunguHelen LachmannAnimesh Singh

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.

Keyphrases

coronavirus disease
inflammatory response
sars cov
respiratory syndrome coronavirus
early onset
high intensity